Connecticut CannaTimesFacts first. You decide.

DCP Faces October 26 Deadline on Testing Transparency and Patient Oversight Petition

A formal petition submitted to Connecticut’s Department of Consumer Protection (DCP) is calling for greater transparency in cannabis safety testing, expanded access to laboratory results, and stronger independent oversight of medical cannabis products.

By Connecticut CannaTimesPublished

Part of Cannabis Testing, Labs and Product Safety · Public Records, FOIA and Transparency

In this storyDCP

Connecticut CannaTimes Editor - October 8, 2026

A formal petition submitted to Connecticut’s Department of Consumer Protection (DCP) is calling for greater transparency in cannabis safety testing, expanded access to laboratory results, and stronger independent oversight of medical cannabis products.

Connecticut Canna Times obtained the September 25, 2026 petition through reader-submitted information. The 15-page submission identifies seven areas for potential agency action, including expanded responsibilities and information access for Connecticut’s Cannabis Ombudsman.

The department acknowledged receipt on September 30 and indicated that a decision would be issued by October 26, 2026.

What is being requested?

The petition separates requests that DCP may be able to implement administratively from proposals requiring formal regulations.

Among its requests:

  1. Remediation transparency: Review cannabis testing records and labels for compliance, and remind establishments to disclose failed tests, retesting, remediation methods and related information where required.

  2. Product Registry improvements: Make safety-testing results searchable, including yeast and mold, Aspergillus, pesticides, heavy metals, mycotoxins and residual solvents, rather than requiring patients to interpret individual laboratory PDFs.

  3. Public testing data: Publish available historical and ongoing testing data through Connecticut’s Open Data Portal, including independent testing conducted by the Connecticut Agricultural Experiment Station (CAES), failed tests and laboratory comparisons. Anonymized records are proposed where confidentiality restrictions apply.

  4. Cannabis Ombudsman access: Establish routine reporting to the Ombudsman covering failed medical cannabis tests, retesting, remediation, laboratory results and relevant CAES findings.

The petition also makes three formal regulatory requests.

Independent testing: Establish a mechanism through which the Cannabis Ombudsman could request independent CAES testing when patient complaints or unusual laboratory findings warrant further examination. The petition suggests approximately 12 products annually as a possible starting point, not a fixed requirement.

Patient-accessible testing histories: Require accessible batch-level records showing original results, failures, subsequent retesting, remediation techniques and associated certificates of analysis.

Permanent testing regulations: Adopt a consolidated regulatory framework addressing cannabis testing standards, remediation, laboratory reporting, labeling, public disclosures and independent oversight.

Why is this different from a complaint?

The submission invokes Connecticut General Statutes § 4-174, which allows interested individuals to formally petition state agencies to adopt, amend or repeal regulations.

DCP’s own petition procedure appears in Regulations of Connecticut State Agencies § 21a-9-10.

Under § 4-174, an agency must act within 30 days of receiving a qualifying petition by either denying it in writing with reasons or initiating formal regulation-making proceedings under § 4-168.

The agency is not required to approve the requested reforms. However, the statute establishes a formal process for considering regulatory petitions.

The October 26 date represents the department’s reported response deadline, not a deadline to finish adopting new regulations.

Why does this matter?

Connecticut already collects substantial cannabis testing information through licensed laboratories, regulatory reporting and independent state testing.

The petition raises a central question: How much of that information should be routinely available to medical patients, the public and the Cannabis Ombudsman?

It also asks whether the existing systems can provide independent verification of testing concerns without transferring enforcement authority away from DCP.

The proposals arrive amid broader questions about Connecticut’s cannabis testing framework and the transition from temporary agency policies and procedures to permanent regulations.

Whether DCP agrees with the proposals remains to be seen.

Connecticut Canna Times will follow the department’s response, expected by October 26, and report whether DCP initiates rulemaking, denies the requests, or identifies measures it can implement administratively.

Connecticut Canna Times

Facts First. You Decide.

Sources

  1. Reader-submitted petition and related submission information. Connecticut Canna Times has withheld the petitioner’s identity.

This story was originally published by Connecticut CannaTimes on Facebook on October 8, 2026 and was migrated to this website on October 16, 2026. The publication date above is the original date.

More in Cannabis Testing, Labs and Product Safety

The full investigation
  1. Correction and Update: The State Cannabis Reference Lab Is Not New
  2. Connecticut Has Quietly Tested Hundreds of Cannabis Products. Now It Is Expanding Its Reference Lab
  3. New COA Access Tool for Connecticut Cannabis Test Results Now in Beta